Evolus, Inc. (EOLS)

NASDAQ: EOLS · IEX Real-Time Price · USD
6.98
-0.35 (-4.77%)
At close: Dec 5, 2022 4:00 PM
7.81
+0.83 (11.89%)
After-hours: Dec 5, 2022 6:04 PM EST
-4.77%
Market Cap 412.29M
Revenue (ttm) 139.63M
Net Income (ttm) -79.43M
Shares Out 56.18M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 391,572
Open 7.22
Previous Close 7.33
Day's Range 6.93 - 7.33
52-Week Range 5.06 - 14.34
Beta 1.94
Analysts Buy
Price Target 16.58 (+137.5%)
Earnings Date Nov 8, 2022

About EOLS

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California. [Read more]

Industry Pharmaceuticals
IPO Date Feb 8, 2018
CEO David Moatazedi
Employees 213
Stock Exchange NASDAQ
Ticker Symbol EOLS
Full Company Profile

Financial Performance

In 2021, Evolus's revenue was $99.67 million, an increase of 76.29% compared to the previous year's $56.54 million. Losses were -$46.81 million, -71.28% less than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for EOLS stock is "Buy." The 12-month stock price forecast is 16.58, which is an increase of 137.54% from the latest price.

Price Target
$16.58
(137.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -18.52% and 8.22%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Evolus Reports Third Quarter 2022 Results and Provides Business Update

NEWPORT BEACH, Calif.

3 weeks ago - Business Wire

Evolus to Participate in November Conferences

NEWPORT BEACH, Calif.

1 month ago - Business Wire

Evolus to Report Third Quarter 2022 Results and Provide Business Update

NEWPORT BEACH, Calif.

1 month ago - Business Wire

Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc., launched commercial operations in Great Britain and shipped the first customer orders for Nuceiva®▼(botulinum toxin type A) last month.

2 months ago - Business Wire

Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus celebrates the conclusion of certain royalty payments that resulted from the 2021 settlement of litigation claims.

2 months ago - Business Wire

Evolus Announces Inducement Grants for New Chief Financial Officer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus today announced inducement grants for its new Chief Financial Officer Sandra Beaver.

2 months ago - Business Wire

Evolus Appoints Sandra Beaver as Chief Financial Officer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc. has named Sandra Beaver as its Chief Financial Officer, effective September 5, 2022.

3 months ago - Business Wire

Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that members of its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference.

3 months ago - Business Wire

Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Newly Published Post Hoc Analysis Evaluates Efficacy of Evolus' Jeuveau® in Adult Males Compared to BOTOX®

3 months ago - Business Wire

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -58.33% and 0.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Evolus Reports Second Quarter 2022 Results and Provides Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus reports financial results for the second quarter ended June 30, 2022 and provides a business update.

4 months ago - Business Wire

Evolus to Report Second Quarter 2022 Results and Provide Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces it will report its second quarter 2022 financial results and provide a business update on Tuesday, August 2, 2022, before market.

4 months ago - Business Wire

Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus launches new consumer engagement campaign offering Jeuveau discounts and challenging consumers to "Switch Your Tox and Love Evolus Forever."

4 months ago - Business Wire

Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus has completed patient enrollment in its clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau®.

4 months ago - Business Wire

Does Evolus, Inc. (EOLS) Have the Potential to Rally 28% as Wall Street Analysts Expect?

The mean of analysts' price targets for Evolus, Inc. (EOLS) points to a 28.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy...

5 months ago - Zacks Investment Research

Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Po...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announced that Dermatologic Surgery published a post hoc analysis of its Phase III studies comparing millennial patients to non-millennials.

6 months ago - Business Wire

Has Evolus (EOLS) Outpaced Other Medical Stocks This Year?

Here is how Evolus, Inc. (EOLS) and Computer Programs and Systems (CPSI) have performed compared to their sector so far this year.

6 months ago - Zacks Investment Research

Wall Street Analysts Predict a 34% Upside in Evolus, Inc. (EOLS): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Evolus, Inc. (EOLS). While the effectiveness of this highly sought-after metric is questionable, the pos...

6 months ago - Zacks Investment Research

Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc., today celebrates the three-year anniversary of the launch of its flagship neurotoxin product, Jeuveau® (prabotulinumtoxinA-xvfs).

6 months ago - Business Wire

Evolus to Participate in the H.C. Wainwright Global Investment Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that members of its management team will be participating in the H.C. Wainwright Global Investment Conference.

6 months ago - Business Wire

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 34.15% and 12.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Evolus Reports First Quarter 2022 Results and Provides Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus reports financial results for the first quarter ended March 31, 2022 and provides a business update.

6 months ago - Business Wire

Evolus to Report First Quarter 2022 Results and Provide Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it will report its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022.

7 months ago - Business Wire

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus enrolls its first patient in a clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs).

8 months ago - Business Wire